JAGX: Jaguar Health Inc. Stocks News on November 27, 2025

JAGX

MT Newswires

7 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

JAGX

MT Newswires

7 days ago

Sector Update: Health Care

JAGX

MT Newswires

7 days ago

Jaguar Health's Napo Pharmaceuticals Submits Amended Crofelemer Trial Protocol to FDA

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

JAGX

ACCESS Newswire

7 days ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

JAGX

GuruFocus.com

10 days ago

Jaguar Health Inc (JAGX) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Ongoing Challenges

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

JAGX

ACCESS Newswire

10 days ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

JAGX

ACCESS Newswire

21 days ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JAGX

ACCESS Newswire

a month ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

JAGX

ACCESS Newswire

2 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

JAGX

ACCESS Newswire

3 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs

JAGX

TipRanks

5 months ago

Jaguar Health to pursue approval of Canalevia in EU for general diarrhea in dogs

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

JAGX

ACCESS Newswire

5 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

JAGX

MT Newswires

5 months ago

Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

JAGX

ACCESS Newswire

5 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

JAGX

ACCESS Newswire

5 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

JAGX

ACCESS Newswire

5 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

JAGX

GlobeNewswire

5 months ago

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

JAGX

MT Newswires

6 months ago

Jaguar Health Establishes First Site for Canalevia-CA1 Field Study

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

JAGX

ACCESS Newswire

6 months ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

JAGX

ACCESS Newswire

6 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

JAGX

ACCESS Newswire

6 months ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series

JAGX

ACCESS Newswire

6 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series

JAGX

MT Newswires

6 months ago

Jaguar Health Prices Offering of Shares, Warrants

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

JAGX

ACCESS Newswire

6 months ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

JAGX

ACCESS Newswire

6 months ago

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

JAGX

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Jaguar Health Inc Earnings Call

JAGX

GuruFocus.com

6 months ago

Jaguar Health Inc (JAGX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Promising ...

Jaguar Health Reports First Quarter 2025 Financials

JAGX

ACCESS Newswire

6 months ago

Jaguar Health Reports First Quarter 2025 Financials

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

JAGX

ACCESS Newswire

6 months ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

JAGX

ACCESS Newswire

7 months ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

JAGX

ACCESS Newswire

7 months ago

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

JAGX

ACCESS Newswire

7 months ago

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

JAGX

ACCESS Newswire

7 months ago

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

JAGX

ACCESS Newswire

7 months ago

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

JAGX

ACCESS Newswire

7 months ago

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Jaguar Health to present results from OnTarget study in breast cancer patients

JAGX

TipRanks

7 months ago

Jaguar Health to present results from OnTarget study in breast cancer patients

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

JAGX

ACCESS Newswire

7 months ago

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

JAGX

ACCESS Newswire

8 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

JAGX

ACCESS Newswire

8 months ago

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

JAGX

MT Newswires

8 months ago

Sector Update: Health Care

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

JAGX

MT Newswires

8 months ago

Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

JAGX

ACCESS Newswire

8 months ago

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

JAGX

GlobeNewswire

8 months ago

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

JAGX

MT Newswires

8 months ago

Jaguar Health to Implement 1-for-25 Reverse Stock Split

Jaguar Health, Inc. Announces Reverse Stock Split

JAGX

ACCESS Newswire

8 months ago

Jaguar Health, Inc. Announces Reverse Stock Split

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

JAGX

ACCESS Newswire

8 months ago

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

JAGX

ACCESS Newswire

9 months ago

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

JAGX

ACCESS Newswire

9 months ago

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

JAGX

ACCESS Newswire

9 months ago

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

JAGX

GlobeNewswire

9 months ago

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

JAGX

ACCESS Newswire

9 months ago

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

JAGX

ACCESS Newswire

10 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

JAGX

ACCESS Newswire

10 months ago

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

JAGX

ACCESS Newswire

10 months ago

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

JAGX

ACCESS Newswire

10 months ago

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

JAGX

ACCESSWIRE

a year ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

JAGX

ACCESSWIRE

a year ago

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

JAGX

ACCESSWIRE

a year ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

JAGX

ACCESSWIRE

a year ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

JAGX

ACCESSWIRE

a year ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

JAGX

ACCESSWIRE

a year ago

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

JAGX

CNW Group

a year ago

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

JAGX

ACCESSWIRE

a year ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

a year ago

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

a year ago

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

JAGX

ACCESSWIRE

a year ago

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

JAGX

ACCESSWIRE

a year ago

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

JAGX

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

JAGX

ACCESSWIRE

a year ago

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

JAGX

ACCESSWIRE

a year ago

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

JAGX

ACCESSWIRE

a year ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

JAGX

ACCESSWIRE

a year ago

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

JAGX

Simply Wall St.

a year ago

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

JAGX

GuruFocus.com

a year ago

Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Jaguar Health Reports Third Quarter 2024 Financial Results

JAGX

ACCESSWIRE

a year ago

Jaguar Health Reports Third Quarter 2024 Financial Results

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

JAGX

ACCESSWIRE

a year ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

JAGX

ACCESSWIRE

a year ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

a year ago

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

$Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting$

JAGX

ACCESSWIRE

a year ago

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

JAGX

ACCESSWIRE

a year ago

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

JAGX

ACCESSWIRE

a year ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

JAGX

ACCESSWIRE

a year ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

JAGX

GuruFocus.com

a year ago

Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

JAGX

ACCESSWIRE

a year ago

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup

JAGX

Clinical Trials Arena

a year ago

Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

JAGX

ACCESSWIRE

a year ago

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

JAGX

ACCESSWIRE

a year ago

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

JAGX

ACCESSWIRE

a year ago

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

JAGX

ACCESSWIRE

a year ago

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

JAGX

ACCESSWIRE

a year ago

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

JAGX

ACCESSWIRE

a year ago

Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

JAGX

ACCESSWIRE

a year ago

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

JAGX

ACCESSWIRE

a year ago

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones

JAGX

ACCESSWIRE

a year ago

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones

JAGX

MT Newswires

a year ago

Latest Jaguar Health Inc. (JAGX) News on November 27, 2025

Share on Social Networks: